GlobalData analyst Shehroz Mahmood notes that Novo Nordisk's amycretin could become the "next frontier" in obesity and T2D.

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

Contineum Therapeutics’ M1 antagonist, PIPE-307, has failed to meet its primary and secondary efficacy endpoints in a Phase II trial in RRMS. Image credit: Andrzej Rostek via ShutterStock.com.

Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting ...

The potential of digital twin technology is growing within the clinical trials landscape. Image credit: Gorodenkoff via ShutterStock.com. In recent years, automation and artificial intelligence (AI) ...

The efficacy evaluable data set comprised 21 participants. Credit: NMK-Studio/Shutterstock.com. Synthekine has reported positive initial data from a Phase Ia/Ib trial evaluating STK-012 in first-line, ...

AbbVie’s star immunology asset, Rinvoq, has posted two more Phase III wins – this time in non-segmental vitiligo (NSV). Image credit: Doralin Samuel Tunas via Shutterstock.com. AbbVie may see its star ...

Part one will enrol around 100 subjects with at least one food allergy: egg, milk, peanut, cashew or walnut. Credit: Chokniti-Studio / Shutterstock.com. RAPT Therapeutics has commenced the prestIgE ...

Japanese pharmaceutical company Takeda has withdrawn itself from the cell therapy space amid its efforts to prioritise its portfolio. Image credit: Anusorn Nakdee via ShutterStock.com. Japanese pharma ...

The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 21.8% from $2.4bn in 2023 to $17bn by 2033. Image credit: Antonio Marca / Shutterstock.com Eli Lilly ...

The proposed clinical trials are expected to address evidence gaps and involve individuals and communities in their design. Credit: Ihar Halavach / Shutterstock.com. Major medical research funders are ...